Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb

Indication
Autoimmune Pulmonary Alveolar Proteinosis

Other upcoming events for SVRA

Phase 3 ReadoutPhase 3 Topline: An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramosti

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb — SVRA Phase 3 Readout | BioSniper